Full Title
A Randomized Phase 2 Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaPurpose
Researchers want to learn if casdozokitug plus toripalimab and bevacizumab is a safe treatment that works well against liver cancer. The people in this study have liver cancer (hepatocellular carcinoma, HCC) that is inoperable (cannot be removed surgically) or has metastasized (spread). The researchers also want to find the best dose of casdozokitug when given with toripalimab and bevacizumab.
Casdozokitug blocks an immune system protein called IL-27. By binding to and blocking IL-27, casdozokitug may help immune cells fight cancer. Toripalimab also helps the immune system fight cancer. Bevacizumab prevents the growth of new blood vessels that feed the cancer. All three drugs are given intravenously (by vein).
If you take part in this study, you will be randomly assigned to get one of these treatments:
- A lower dose of casdozokitug in combination with toripalimab and bevacizumab
- A higher dose of casdozokitug in combination with toripalimab and bevacizumab
- Toripalimab and bevacizumab only (without casdozokitug)
Who Can Join
To join this study, there are a few conditions. You must:
- Have HCC that is inoperable or metastatic.
- Have HCC that cannot be cured with surgery or local therapies.
- Not have previously received anti-cancer medications for HCC.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information and to see if you can join this study, please call Dr. Ghassan Abou-Alfa’s office at 646-888-4184.